Positive allosteric modulation of the human cannabinoid (CB 1) receptor by RTI-371, a selective inhibitor of the dopamine transporter

British Journal of Pharmacology

Volumn 156, Issue 7, 2009, Pages 1178-1184

  Navarro, Hernán A ^a   Howard, James L ^b   Pollard, Gerald T ^b   Carroll, F Ivy ^a  

^a RTI INTERNATIONAL   (United States)

^b Howard Associates LLC   (United States)

Author keywords

3 phenyltropane; Allosteric modulation; Calcium mobilization; Cannabinoid receptor

Indexed keywords

3B(4 METHYLPHENYL) 2B [3 (4 CHLOROPHENYL)ISOXAZOL 5 YL]TROPANE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; COCAINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; MU OPIATE RECEPTOR; RTI 371; UNCLASSIFIED DRUG; 3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; 3BETA (4 METHYLPHENYL) 2BETA (3 (4 CHLOROPHENYL)ISOXAZOL 5 YL)TROPANE; 3BETA-(4-METHYLPHENYL)-2BETA-(3-(4-CHLOROPHENYL)ISOXAZOL-5-YL)TROPANE; CALCIUM; CYCLOHEXANOL DERIVATIVE; ISOXAZOLE DERIVATIVE; TROPANE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG SCREENING; DRUG SPECIFICITY; HUMAN; HUMAN CELL; LOCOMOTION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; ALLOSTERISM; ANIMAL; CHO CELL; CRICETULUS; DRUG ANTAGONISM; DRUG POTENTIATION; HAMSTER; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY;

ALLOSTERIC REGULATION; ANIMALS; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOHEXANOLS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; ISOXAZOLES; MALE; MICE; MOTOR ACTIVITY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; TROPANES;

EID: 67650648706     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00124.x     Document Type: Article

References (39)

1. Agoston GE, Wu JH, Izenwasser S, George C, Katz J, Kline RH et al. (1997). Novel N-substituted 3 alpha-[bis(4′-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter. J Med Chem 40 (26 4329 4339. (Pubitemid 28042312)
2. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2 S1 S209.
3. Bergman J, Madras BK, Johnson SE, Spealman RD (1989). Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251 (1 150 155. (Pubitemid 19261957)
4. Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA et al. (1995). Cocaine and 3β-(4′-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 38 (2 379 388.
5. Carroll FI, Pawlush N, Kuhar MJ, Pollard GT, Howard JL (2004a). Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3′-substituted isoxazol-5-yl)tropanes. J Med Chem 47 (2 296 302.
6. Carroll FI, Runyon SP, Abraham P, Navarro H, Kuhar MJ, Pollard GT et al. (2004b). Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers. J Med Chem 47 (25 6401 6409.
7. Carroll FI, Fox BS, Kuhar MJ, Howard JL, Pollard GT, Schenk S (2006a). Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration. Eur J Pharmacol 553 (1-3 149 156.
8. Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ (2006b). Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J 8 (1 E196 E203.
9. Christopoulos A, Sorman JL, Mitchelson F, El-Fakahany EE (1999). Characterization of the subtype selectivity of the allosteric modulator heptane-1,7-bis-(dimethyl-3′-phthalimidopropyl) ammonium bromide (C7/3-phth) at cloned muscarinic acetylcholine receptors. Biochem Pharmacol 57 (2 171 179.
10. Cook CD, Carroll FI, Beardsley PM (2002). RTI 113, a 3-phenyltropane analog, produces long-lasting cocaine-like discriminative stimulus effects in rats and squirrel monkeys. Eur J Pharmacol 442 (1-2 93 98.
11. De Petrocellis L, Cascio MG, Di Marzo V (2004). The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141 (5 765 774.
12. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL (2005). Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25 (8 1889 1893.
13. Fernandez-Ruiz J, Gonzales S (2005). Cannabinoid control of motor function at the basal ganglia. Handb Exp Pharmacol 168 : 479 507.
14. Fernandez-Ruiz J, Lastres-Becker I, Cabranes A, Gonzalez S, Ramos JA (2002). Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 66 (2-3 257 267.
15. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A (2003). Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci 18 (6 1607 1614.
16. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2 (4 358 363.
17. Gu H, Wall SC, Rudnick G (1994). Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269 (10 7124 7130.
18. Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ et al. (2007). PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152 (5 805 814.
19. Howlett AC (2005). Cannabinoid receptor signaling. Handb Exp Pharmacol 168 : 53 79.
20. Jensen AA, Spalding TA (2004). Allosteric modulation of G-protein coupled receptors. Eur J Pharm Sci 21 (4 407 420.
21. Katz JL, Kopajtic TA, Agoston GE, Newman AH (2004). Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J Pharmacol Exp Ther 309 (2 650 660.
22. Koe BK (1976). Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J Pharmacol Exp Ther 199 (3 649 661.
23. Koetzner L, Riley AL, Glowa JR (1996). Discriminative stimulus effects of dopaminergic agents in rhesus monkeys. Pharmacol Biochem Behav 54 (2 517 523.
24. Kuhar MJ, Ritz MC, Boja JW (1991). The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14 (7 299 302.
25. Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Perez-Rosado A, Manzanares J et al. (2002). Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 44 (1 23 35.
26. Madras BK, Fahey MA, Bergman J, Canfield DR, Spealman RD (1989). Effects of cocaine and related drugs in nonhuman primates. I. [3H]cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 251 (1 131 141. (Pubitemid 19261955)
27. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK et al. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40 (3 471 478.
28. Navarro H, Howard J, Pollard G, Carroll F (2005). The DAT-selective 3-phenyltropane, RTI-371, antagonizes the in vivo effects of cocaine. 67th Annual Meeting of the College on Problems of Drug Dependence, 124.
29. Newman AH, Kulkarni S (2002). Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic - a focus on analogues of benztropine and rimcazole. Med Res Rev 22 (5 429 464.
30. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R et al. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68 (5 1484 1495.
31. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987). Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237 (4819 1219 1223.
32. Romero J, Garcia L, Cebeira M, Zadrozny D, Fernandez-Ruiz JJ, Ramos JA (1995). The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci 56 (23-24 2033 2040.
33. Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernandez-Ruiz J (2002). The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 95 (2 137 152.
34. Runyon SP, Carroll FI (2006). Dopamine transporter ligands: recent developments and therapeutic potential. Curr Top Med Chem 6 (17 1825 1843.
35. Substance Abuse and Mental Health Services Administration (2006). Results from the 2005 National Survey on Drug Use and Health: National Findings. NSDUH Series H-30. DHHS Publication No. SMA 06-4194. Office of Applied Studies : Rockville, MD.
36. Tamiz AP, Bandyopadhyay BC, Zhang J, Flippen-Anderson JL, Zhang M, Wang CZ et al. (2001). Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors. J Med Chem 44 (10 1615 1622.
37. Tanda G, Ebbs AL, Kopajtic TA, Elias LM, Campbell BL, Newman AH et al. (2007). Effects of muscarinic M1 receptor blockade on cocaine-induced elevations of brain dopamine levels and locomotor behavior in rats. J Pharmacol Exp Ther 321 (1 334 344.
38. Volkow N, Li TK (2005). The neuroscience of addiction. Nat Neurosci 8 (11 1429 1430.
39. Wise RA (1984). Neural mechanisms of the reinforcing action of cocaine. NIDA Res Monogr 50 : 15 33.